Liu H, Golji J, Brodeur LK, et al. Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss. Nat Med. 2019;25(1):95-102. doi:10.1038/s41591-018-0302-5
Nechama M, Kwon J, Wei S, et al. The IL-33-PIN1-IRAK-M axis is critical for type 2 immunity in IL-33-induced allergic airway inflammation. Nat Commun. 2018;9(1):1603. doi:10.1038/s41467-018-03886-6
Huang J, Zhu H, Haggarty SJ, et al. Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips. Proc Natl Acad Sci U S A. 2004;101(47):16594-9. doi:10.1073/pnas.0407117101
Martins MM, Zhou AY, Corella A, et al. Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map. Cancer Discov. 2015;5(2):154-67. doi:10.1158/2159-8290.CD-14-0552
Schreiber SL, Crabtree GR. Immunophilins, ligands, and the control of signal transduction. Harvey Lect. 1995;91:99-114.
Spencer DM, Graef I, Austin DJ, Schreiber SL, Crabtree GR. A general strategy for producing conditional alleles of Src-like tyrosine kinases. Proc Natl Acad Sci U S A. 1995;92(21):9805-9.
Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017;168(6):960-976. doi:10.1016/j.cell.2017.02.004
Liu D, Albergante L, Newman TJ. Universal attenuators and their interactions with feedback loops in gene regulatory networks. Nucleic Acids Res. 2017;45(12):7078-7093. doi:10.1093/nar/gkx485
Wu Y, Dissing-Olesen L, MacVicar BA, Stevens B. Microglia: Dynamic Mediators of Synapse Development and Plasticity. Trends Immunol. 2015;36(10):605-13. doi:10.1016/j.it.2015.08.008
Lumpkin RJ, Gu H, Zhu Y, et al. Site-specific identification and quantitation of endogenous SUMO modifications under native conditions. Nat Commun. 2017;8(1):1171. doi:10.1038/s41467-017-01271-3